News
Media
Conferences
CME/CE
Partners
Publications
Resources
Subscribe

|Videos|March 11, 2021

Virtual Exam Findings in an Infant Affected by Spinal Muscular Atrophy

Author(s)Diana Castro, MD, Garey H. Noritz, MD

Garey H. Noritz, MD, walks us through a virtual pediatric neurological exam and notes examination findings that may be identified in an infant with Spinal Muscular Atrophy (SMA).

Episodes in this series

EP. 1 Pediatric Neurological Exam to Identify SMA

EP. 1 Pediatric Neurological Exam to Identify SMA

EP. 2 Virtual Exam Findings in an Infant Affected by Spinal Muscular Atrophy

EP. 2 Virtual Exam Findings in an Infant Affected by Spinal Muscular Atrophy

EP. 3 Referral of SMA to a Neurologist

EP. 3 Referral of SMA to a Neurologist

EP. 4 Newborn Screening for SMA

EP. 4 Newborn Screening for SMA

EP. 5 Signs and Symptoms of SMA

EP. 5 Signs and Symptoms of SMA

EP. 6 Evaluation of Suspected SMA via In-Person and Remote Exam

EP. 6 Evaluation of Suspected SMA via In-Person and Remote Exam

EP. 7 Discussing the Diagnosis of SMA With the Family

EP. 7 Discussing the Diagnosis of SMA With the Family

EP. 8 SMA Resources for Physicians and Families

EP. 8 SMA Resources for Physicians and Families

EP. 9 Telehealth During COVID-19

EP. 9 Telehealth During COVID-19

EP. 10 Importance of Follow-Up Visits for SMA Amid COVID-19

EP. 10 Importance of Follow-Up Visits for SMA Amid COVID-19

EP. 11 Advice to Community Neurologists Treating SMA

EP. 11 Advice to Community Neurologists Treating SMA

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Related Content

Comparative Study Reveals Psychiatric Comorbidities Common in MOGAD, MS, and NMOSD, With Distinct Timing Patterns

ByIsabella Ciccone, MPH

February 6th 2026

NeurologyLive® Friday 5 — February 6, 2026

ByIsabella Ciccone, MPH

February 6th 2026

Phase 3b RESHAPE Study Evaluates Risk–Benefit of Switching From Ocrelizumab to BTK Inhibitor Remibrutinib

ByIsabella Ciccone, MPH

February 6th 2026

Myelin Protective Small Molecule Lucid-MS Shows Promising Early-Stage Data in Healthy Volunteers

February 6th 2026

Using Human iPSC Models to Dissect PIRA Mechanisms in Progressive Multiple Sclerosis: Valentina Fossati, PhD

ByValentina Fossati, PhD

February 6th 2026

Latest CME

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Estelamari Rodriguez, MD, MPH; Millie Das, MD; Ruham Nasany, MD

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Anne Chiang, MD, PhD; J. Douglas Miles, MD, PhD, FAAN; Suma Satti, MD

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

Abigail N. Schwaede, MD; Emmanuelle (Noelle) Tiongson, MD

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

Shamik Bhattacharyya, MD, MS, FAAN; Mirla Avila, MD; Dean Wingerchuk, MD

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

Richard Bedlack, MD, PhD

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

Terry Heiman-Patterson, MD

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

Cladribine Tablets Show Ability to Improve or Stabilize Cognitive Function in Patients With Relapsing Multiple Sclerosis

Myelin Protective Small Molecule Lucid-MS Shows Promising Early-Stage Data in Healthy Volunteers

Using Human iPSC Models to Dissect PIRA Mechanisms in Progressive Multiple Sclerosis: Valentina Fossati, PhD

Cladribine Maintains Efficacy, Safety Profile in Older Patients With Multiple Sclerosis

Phase 3b RESHAPE Study Evaluates Risk–Benefit of Switching From Ocrelizumab to BTK Inhibitor Remibrutinib